Pfizer Takes 3% Stake In Sosei On Back Of Heptares GPCR Deal
This article was originally published in Scrip
Executive Summary
Heptares Therapeutics, a Sosei Group subsidiary, has entered a deal to apply its drug discovery technology to 10 G protein-coupled receptor (GPCR) targets selected by Pfizer Inc. across a number therapeutic areas. The deal also sees Pfizer acquiring a 3% equity stake in Sosei.
You may also be interested in...
Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation
An undisclosed G-protein coupled receptor playing a role in inflammatory disease will be the focus of a drug pact between Heptares and PeptiDream.
Heptares-Powered Sosei's Incoming CEO Explains What Happens Next
Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.